E2F7: A Potential Drug Target and Biomarker (G144455)

Target Name: E2F7

NCBI ID: G144455

E2F7

Other Name(s): E2F-7 | Transcription factor E2F7 | E2F transcription factor 7 | E2F7_HUMAN | FLJ12981

E2F7: A Potential Drug Target and Biomarker

E2F7, also known as E2F-7, is a protein that is expressed in various tissues and cells throughout the body. It is a key regulator of the cell cycle, which means it plays a critical role in the growth, development, and division of cells. Mutations in the E2F7 gene have been linked to various diseases, including cancer, neurodegenerative diseases, and developmental disorders. As a result, E2F7 has emerged as a promising drug target and biomarker.

The E2F7 gene is located on chromosome 18q21 and encodes a protein that contains 215 amino acid residues. The protein has a molecular weight of 31 kDa and a calculated pI of 4.85. It is composed of a unique N-terminal domain that contains a conserved nucleotide and a C-terminal domain that contains a unique acidic amino acid residue. The C-terminal domain is the region of interest in this study.

The C-terminal domain of E2F7 contains a unique acidic amino acid residue, which is important for its structural stability and function. The acidic amino acid residue is located at position 208 and has a pI of 4.95. It is part of a region that is involved in the formation of a disulfide bond, which is a common structural feature in proteins that involves the formation of a covalent bond between two amino acids. The acidic residue is also involved in the stability of the protein, as it is able to donate a proton to other amino acids in the protein, which can help to maintain the overall stability of the protein.

In addition to its structural features, the acidic amino acid residue of E2F7 is also involved in its function. It is known to play a role in the regulation of the cell cycle, as well as the regulation of cell growth and differentiation. Studies have shown that the acidic amino acid residue of E2F7 is able to interact with other proteins that are involved in the cell cycle and in the regulation of cell growth. These interactions may help to regulate the cell cycle and ensure that cells are able to divide and grow properly.

The potential drug target for E2F7 is its role in the regulation of the cell cycle. Cancer cells are able to bypass the normal cell cycle regulation by mutating the E2F7 gene. This allows the cells to continue to divide and grow uncontrollably. As a result, targeting E2F7 with drugs that inhibit its function in the cell cycle could be an effective way to treat various types of cancer.

In addition to its potential as a drug target, E2F7 has also been identified as a potential biomarker. The acidic amino acid residue of E2F7 is able to interact with proteins that are involved in the regulation of the cell cycle, which may be useful as a biomarker for various types of cancer. For example, altered levels of E2F7 have been observed in various types of cancer, including breast cancer, lung cancer, and colorectal cancer. Additionally, some studies have shown that the acidic amino acid residue of E2F7 is able to interact with proteins that are involved in the regulation of cell growth, which may be another potential biomarker for cancer.

Overall, E2F7 is a protein that has significant potential as a drug target and biomarker. Its unique acidic amino acid residue, as well as its role in the regulation of the cell cycle, make it an attractive target for small molecules that are able to inhibit its function. Further research is needed to

Protein Name: E2F Transcription Factor 7

Functions: Atypical E2F transcription factor that participates in various processes such as angiogenesis, polyploidization of specialized cells and DNA damage response. Mainly acts as a transcription repressor that binds DNA independently of DP proteins and specifically recognizes the E2 recognition site 5'-TTTC[CG]CGC-3'. Directly represses transcription of classical E2F transcription factors such as E2F1. Acts as a regulator of S-phase by recognizing and binding the E2-related site 5'-TTCCCGCC-3' and mediating repression of G1/S-regulated genes. Plays a key role in polyploidization of cells in placenta and liver by regulating the endocycle, probably by repressing genes promoting cytokinesis and antagonizing action of classical E2F proteins (E2F1, E2F2 and/or E2F3). Required for placental development by promoting polyploidization of trophoblast giant cells. Also involved in DNA damage response: up-regulated by p53/TP53 following genotoxic stress and acts as a downstream effector of p53/TP53-dependent repression by mediating repression of indirect p53/TP53 target genes involved in DNA replication. Acts as a promoter of sprouting angiogenesis, possibly by acting as a transcription activator: associates with HIF1A, recognizes and binds the VEGFA promoter, which is different from canonical E2 recognition site, and activates expression of the VEGFA gene. Acts as a negative regulator of keratinocyte differentiation

The "E2F7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about E2F7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets